BiotechTube
Igyxos Biotherapeutics

Igyxos Biotherapeutics

Paris, France· Est.
igyxos.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Igyxos Biotherapeutics is a private, preclinical-stage biotech focused on developing first-in-class monoclonal antibody therapies for infertility. Its lead candidate, IGX12, is designed to boost the bioactivity of Follicle Stimulating Hormone (FSH) to improve the efficacy of assisted reproductive technologies. The company leverages a unique scientific approach spun out of earlier animal health research and is backed by French institutional investors including BPI France, Go Capital, and UI Investissement.

InfertilityReproductive Health

Technology Platform

Monoclonal antibody platform targeting gonadotropins (e.g., FSH) to enhance hormone receptor binding and bioactivity via conformational change.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The large and growing global infertility market, with 186 million individuals affected, presents a significant opportunity for a novel therapy that improves IVF success rates or efficiency.
An FSH-enhancing antibody could reduce treatment costs and burden, potentially expanding access and capturing substantial value within the multi-billion dollar ART industry.

Risk Factors

Key risks include the high failure rate of preclinical assets in clinical translation, regulatory hurdles for a first-in-class fertility drug, and challenges in pricing and reimbursement within cost-conscious healthcare systems.
The company also faces pipeline concentration risk with a single lead candidate.

Competitive Landscape

The competitive landscape for novel infertility drugs is moderately crowded but focused on different mechanisms (e.g., oral GnRH antagonists, new recombinant hormones). Igyxos's antibody-based FSH enhancer appears to be a first-in-class approach, potentially competing against standard recombinant FSH products by aiming to improve their efficacy rather than directly replacing them.

More companies in Biologics / Biosimilars →More companies in France →